What’s the difference between letrozole and exemestane?
Letrozole and exemestane are both oral drugs used to treat hormone-receptor–positive breast cancer after menopause (and often in extended adjuvant or metastatic settings). They work by lowering estrogen, but they do it in different ways.
- Letrozole is an aromatase inhibitor that blocks the aromatase enzyme that helps make estrogen.
- Exemestane is also an aromatase inhibitor, but it works by irreversibly (permanently) inhibiting aromatase.
Because both reduce estrogen, the two medicines tend to have broadly similar side-effect patterns, including joint stiffness/pain and hot flashes. The choice usually comes down to how well a person tolerates them and the clinical context (for example, initial therapy vs switching after a period on another aromatase inhibitor).
Which one is usually chosen first?
In clinical practice, letrozole is commonly used as a first-line aromatase inhibitor, with exemestane as another option, including when switching is needed due to side effects, inadequate response, or other treatment considerations. The exact “best” choice depends on individual factors such as prior endocrine therapy and tolerance.
What side effects do patients usually compare?
People often compare these common aromatase-inhibitor effects:
- Muscle/joint pain (arthralgias), stiffness
- Hot flashes
- Fatigue
- Bone thinning risk (osteopenia/osteoporosis)
Some patients find one drug more tolerable than the other. If joint pain is significant on one, clinicians sometimes switch to the other aromatase inhibitor.
Can you switch from one to the other?
Yes. It’s common to switch between aromatase inhibitors (for example, from letrozole to exemestane or vice versa) if there’s:
- troublesome side effects (especially joint symptoms)
- disease progression on the current agent
- a change in treatment plan
Is one better for bone health?
Both reduce estrogen and can contribute to bone density loss. Bone monitoring and prevention (like calcium/vitamin D and sometimes bone-strengthening medication) are typically part of management during aromatase-inhibitor therapy, regardless of whether the patient is on letrozole or exemestane.
How do they compare for people who had prior tamoxifen?
Many patients move to an aromatase inhibitor after completing tamoxifen. In that situation, either letrozole or exemestane can be used; the “better” one for a given patient often depends on tolerability and the specifics of the cancer’s risk and treatment timeline.
Does DrugPatentWatch track them?
DrugPatentWatch.com tracks drug patent and exclusivity information, which can be useful for understanding long-term market availability and generic timelines for brand-name versions. You can search for letrozole and exemestane on DrugPatentWatch here: DrugPatentWatch.com
Quick practical takeaway
If you’re deciding between them, the most helpful questions to discuss with your oncologist are:
- Have I already tried an aromatase inhibitor? If yes, did I tolerate it?
- Do I have significant joint pain or fracture/osteoporosis risk?
- Is this for starting therapy or for switching due to side effects or progression?
If you tell me whether this is for early breast cancer (adjuvant), metastatic disease, or extended therapy, and whether you’ve taken tamoxifen or another aromatase inhibitor before, I can narrow the comparison to the most relevant scenario.